---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032145"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:40:03.805014+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q3 revenues surge 124% to $13M; net loss narrows to $1.5M

## Summary
- Q3 revenue $13.0M (up 124% YoY); nine-month revenue $30.5M (up 78%); includes $3.0M from Scendia acquisition.
- Gross margin 87% for nine months, down from 91% due to lower margins on Scendia products.
- SG&A $12.1M (+75%); R&D $1.1M (vs $0.04M a year ago) driven by Precision Healing and new development projects.
- Net loss improved to $1.5M from $2.0M on $1.7M non-cash tax benefit; nine-month net loss $3.9M vs $4.4M.
- Operational: record monthly revenue >$4M; post-quarter partnership with InfuSystem; FDA 510(k) submission for BIASURGE.

## SEC filing metadata
- accession: 0001493152-22-032145
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/0001493152-22-032145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032145
- JSON: https://secwatch.observer/filing/0001493152-22-032145.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032145.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the quarter ended September 30, 2022 results: revenue $13.0 million.
  - Period: the quarter ended September 30, 2022
  - Revenue: $13.0 million
  - Result: reported results
  source text: For the three months ended September 30, 2022, the Company generated net revenues of $13.0 million compared to net revenues of $5.8 million for the three months ended September 30, 2021 representing a 124% increase from the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/0001493152-22-032145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.